United Therapeutics: FDA Approves Tyvaso For PH-ILD

United Therapeutics Corporation (UTHR) announced that FDA has approved Tyvaso Inhalation Solution for the treatment of patients with pulmonary hypertension associated with interstitial lung disease to improve exercise ability. This is the second FDA-approved indication for Tyvaso. It was initially approved for the treatment of pulmonary arterial hypertension.